Literature DB >> 18566102

The immunoadhesin glycoprotein VI-Fc regulates arterial remodelling after mechanical injury in ApoE-/- mice.

Tanja Schönberger1, Dorothea Siegel-Axel, Renate Bussl, Sabine Richter, Martin S Judenhofer, Roland Haubner, Gerald Reischl, Karin Klingel, Götz Münch, Peter Seizer, Bernd J Pichler, Meinrad Gawaz.   

Abstract

AIMS: Rupture of advanced atherosclerotic plaques initiates platelet activation and aggregation as subendothelial collagen is exposed. Platelet collagen receptor glycoprotein VI (GPVI) was found to bind preferentially to the core region of human plaques. Consequently, platelets contribute to inflammatory processes and trigger atherosclerotic lesion progression. In this study, we examined binding of soluble platelet collagen receptor GPVI-Fc to atherosclerotic lesions and its effect on platelet-triggered athero-progression and neointima formation after wire-induced carotid injury. METHODS AND
RESULTS: For binding studies after ligation-induced arterial injury, the left common carotid artery of C57BL/6J mice was ligated. For binding studies at spontaneously formed atherosclerotic lesion sites, Apolipoprotein E-deficient (ApoE(-/-)) mice were fed a 0.25% cholesterol diet over 16 weeks. Binding of [(124)I]GPVI-Fc was monitored by autoradiography 48 h after intravenous injection and by immunostaining. To study the effect of GPVI-Fc on neointima formation vs. control-Fc, a wire-induced injury of the left A. carotis communis of ApoE(-/-)-mice was performed. Mice were treated intraperitoneally with GPVI-Fc for 8 days and neointima formation was assessed 4 weeks after intervention. [(124)I]GPVI-Fc preferentially bound to injury sites after carotid ligation in C57BL/6J mice and to lipid-rich atherosclerotic lesions of the carotid artery and aortic arch in uninjured ApoE(-/-)-mice. Histological examinations of wire-injured carotid arteries showed that neointima formation was significantly reduced in GPVI-Fc-treated ApoE(-/-) mice compared to ApoE(-/-) mice receiving control-Fc (P < 0.05).
CONCLUSION: GPVI-Fc preferentially bound to sites of vascular injury and was able to inhibit neointima formation after wire-induced vascular injury in ApoE(-/-) mice. Thus, soluble GPVI-Fc might be also a promising compound to attenuate lesion progression after plaque rupture.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18566102     DOI: 10.1093/cvr/cvn169

Source DB:  PubMed          Journal:  Cardiovasc Res        ISSN: 0008-6363            Impact factor:   10.787


  8 in total

1.  Inhibition of foam cell formation using a soluble CD68-Fc fusion protein.

Authors:  Karin Daub; Dorothea Siegel-Axel; Tanja Schönberger; Christoph Leder; Peter Seizer; Karin Müller; Martin Schaller; Sandra Penz; Dagmar Menzel; Berthold Büchele; Andreas Bültmann; Götz Münch; Stephan Lindemann; Thomas Simmet; Meinrad Gawaz
Journal:  J Mol Med (Berl)       Date:  2010-05-08       Impact factor: 4.599

Review 2.  Ibrutinib-associated bleeding: pathogenesis, management and risk reduction strategies.

Authors:  J J Shatzel; S R Olson; D L Tao; O J T McCarty; A V Danilov; T G DeLoughery
Journal:  J Thromb Haemost       Date:  2017-03-27       Impact factor: 5.824

3.  Gremlin-1 is an inhibitor of macrophage migration inhibitory factor and attenuates atherosclerotic plaque growth in ApoE-/- Mice.

Authors:  Iris Müller; Tanja Schönberger; Martina Schneider; Oliver Borst; Melanie Ziegler; Peter Seizer; Christoph Leder; Karin Müller; Michael Lang; Florian Appenzeller; Oleg Lunov; Berthold Büchele; Manuela Fahrleitner; Marcus Olbrich; Harald Langer; Tobias Geisler; Florian Lang; Madhumita Chatterjee; Jan Freark de Boer; Uwe J F Tietge; Jürgen Bernhagen; Thomas Simmet; Meinrad Gawaz
Journal:  J Biol Chem       Date:  2013-09-03       Impact factor: 5.157

4.  The GPVI-Fc fusion protein Revacept reduces thrombus formation and improves vascular dysfunction in atherosclerosis without any impact on bleeding times.

Authors:  Martin Ungerer; Zhongmin Li; Christine Baumgartner; Silvia Goebel; Jasmin Vogelmann; Hans-Peter Holthoff; Meinrad Gawaz; Götz Münch
Journal:  PLoS One       Date:  2013-08-12       Impact factor: 3.240

5.  The antiplatelet agent revacept prevents the increase of systemic thromboxane A2 biosynthesis and neointima hyperplasia.

Authors:  Sara Alberti; Qianqian Zhang; Ilaria D'Agostino; Annalisa Bruno; Stefania Tacconelli; Annalisa Contursi; Simone Guarnieri; Melania Dovizio; Lorenza Falcone; Patrizia Ballerini; Götz Münch; Ying Yu; Paola Patrignani
Journal:  Sci Rep       Date:  2020-12-08       Impact factor: 4.379

Review 6.  Targeting Platelet in Atherosclerosis Plaque Formation: Current Knowledge and Future Perspectives.

Authors:  Lei Wang; Chaojun Tang
Journal:  Int J Mol Sci       Date:  2020-12-21       Impact factor: 5.923

7.  Multiparameter Evaluation of the Platelet-Inhibitory Effects of Tyrosine Kinase Inhibitors Used for Cancer Treatment.

Authors:  Bibian M E Tullemans; Alicia Veninga; Delia I Fernandez; Maureen J B Aarts; Johannes A Eble; Paola E J van der Meijden; Johan W M Heemskerk; Marijke J E Kuijpers
Journal:  Int J Mol Sci       Date:  2021-10-18       Impact factor: 5.923

8.  The GPVI-Fc fusion protein Revacept improves cerebral infarct volume and functional outcome in stroke.

Authors:  Silvia Goebel; Zhongmin Li; Jasmin Vogelmann; Hans-Peter Holthoff; Heidrun Degen; Dirk M Hermann; Meinrad Gawaz; Martin Ungerer; Götz Münch
Journal:  PLoS One       Date:  2013-07-23       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.